Publications by authors named "N Sheerin"

Importance: Lengthening waiting lists for organ transplant mandates the development of strategies to expand the deceased donor pool. Due to concerns regarding organ viability, most organ donation organizations internationally wait no longer than 1 to 2 hours for potential donation after circulatory death (DCD), possibly underutilizing an important organ source; UK policy mandates a minimum 3-hour wait time.

Objective: To assess whether time to death (TTD) from withdrawal of life-sustaining treatment (WLST) is associated with kidney transplant outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • The haemolytic uraemic syndromes (HUS) include various conditions, with some linked to complement activation (CaHUS).
  • The 2023 International Society of Nephrology HUS Forum featured experts discussing the latest knowledge, uncertainties, and proposed solutions in diagnosing and managing HUS.
  • Key areas needing research include naming conventions, complement testing, identifying biomarkers, genetic factors for aHUS, treatment strategies for C5 inhibitors, and improving access to care for patients.
View Article and Find Full Text PDF

Introduction: Successful organ transplantation in patients with end-stage organ failure improves long-term survival, improves quality of life and reduces costs to the NHS. Despite an increase in the number of deceased organ donors over the last decade, there remains a considerable shortfall of suitable organs available for transplantation. Over half of UK donors are certified dead by neurological criteria following brain stem compression, which leads to severe physiological stress in the donor, combined with a hyperinflammatory state.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness and safety of eculizumab prophylaxis versus rescue therapy for kidney transplant recipients with atypical hemolytic uremic syndrome (aHUS), analyzing data from Dutch and UK patient cohorts.
  • Results indicated similar graft survival rates between Dutch patients receiving rescue therapy and UK patients on prophylaxis, with Dutch patients showing slightly better outcomes but not significantly different.
  • The findings suggest that in patients with lower genetic risk for recurrence, eculizumab rescue therapy may be as effective as prophylaxis without compromising graft survival.
View Article and Find Full Text PDF